N-(3-氨基丙基)-N-甲基氨基甲酸叔丁酯 | 144222-23-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(3-氨基丙基)-N-甲基氨基甲酸叔丁酯
• 中文别名: 叔丁基(4-氨基丁基)(甲基)氨基甲酸叔丁酯；N-(4-氨基丁基)-N-甲基氨基甲酸叔丁酯；N-(4-氨丁基)-N-甲基氨基甲酸叔丁酯；N-BOC-N-甲基-丁烷-1,4-二胺；N-BOC-N-甲基-丁烷-1,4-二胺柠檬酸盐
• 英文名称: N-(4-aminobutyl)-N-methyl carbamic acid tert-butyl ester
• 英文别名: N-(4-aminobutyl)-N-methylcarbamic acid tert-butyl ester；tert-butyl N-(4-aminobutyl)-N-methylcarbamate；tert-butyl 4-aminobutyl(methyl)carbamate；(4-amino-butyl)-methyl-carbamic acid tert-butyl ester；(4-aminobutyl)methylcarbamic acid tert-butyl ester；4-(N-methyl-N-t-butyl-oxycarbonylamino)butylamine
• CAS: 144222-23-1
• 化学式: C₁₀H₂₂N₂O₂
• mdl: MFCD03001681
• 分子量: 202.297
• InChiKey: CIZQQISFIQZTDF-UHFFFAOYSA-N

物化性质

• 沸点：
  276.6±19.0 °C(Predicted)
• 密度：
  0.972±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  应存放在2-8°C的环境中，避免光照，并保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(4-Aminobutyl)-N-methyl carbamic acid tert-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(4-Aminobutyl)-N-methyl carbamic acid tert-butyl ester
CAS number: 144222-23-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H22N2O2
Molecular weight: 202.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(3-氨基丙基)-N-甲基氨基甲酸叔丁酯 在 磷酸 、 碳酸氢钠 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 水 、 乙腈 为溶剂， 生成 (1S,5R)-2-[4-(methylamino)butylcarbamoyl]-7-oxo-2,6-diazabicyclo[3.2.0]heptane-6-sulfonic acid
  参考文献：
  名称：

  Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712

  摘要：

  The bridged monobactam beta-lactamase inhibitor MK-8712 (1) effectively inhibits class C beta-lactamases. Side chain N-alkylated and ring-opened analogs of 1 were prepared and evaluated for combination with imipenem to overcome class C beta-lactamase mediated resistance. Although some analogs were more potent inhibitors of AmpC, none exhibited better synergy with imipenem than 1. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.065

文献信息

• [EN] METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT DE TROUBLES D'UTILISATION D'ALCOOL ET DE MALADIES ASSOCIÉES
  申请人：PHARMATROPHIX INC

  公开号：WO2018039641A1

  公开（公告）日：2018-03-01

  Methods and compounds for treating alcohol use disorder and associated diseases. Included is the administering to a subject in need there of an effective amount of a compound having a modulating effect on p75NTR.

  治疗酒精使用障碍和相关疾病的方法和化合物。包括向需要的受试者施用对p75NTR具有调节作用的化合物的有效量。
• CXCR4 chemokine receptor binding comounds
  申请人：——

  公开号：US20040209921A1

  公开（公告）日：2004-10-21

  The present invention relates to compounds that bind to chemokine receptors, and having the formula 1 wherein each A, X, Y, R 1 , R 2 and R 3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

  本发明涉及与趋化因子受体结合的化合物，其具有式1的结构，其中A、X、Y、R1、R2和R3均为取代基。本发明还涉及使用这类化合物的方法，例如在治疗HIV感染和炎症性疾病如类风湿性关节炎中的应用。此外，本发明还涉及使用这类化合物来提高祖细胞和干细胞计数的方法，以及提高白细胞计数的方法。
• [EN] INHIBITION OF OLIG2 ACTIVITY<br/>[FR] INHIBITION DE L'ACTIVITÉ D'OLIG2
  申请人：CURTANA PHARMACEUTICALS INC

  公开号：WO2016138479A1

  公开（公告）日：2016-09-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制Olig2的活性。本文还描述了使用这些Olig2抑制剂的方法，单独或与其他化合物结合，用于治疗癌症和其他疾病。特别是Olig2抑制剂可用于治疗胶质母细胞瘤。
• MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1
  申请人：The Scripps Research Institute

  公开号：US20180089049A1

  公开（公告）日：2018-03-29

  Transcriptomes provide a myriad of potential RNAs that could be the targets of therapeutics or chemical genetic probes of function. Cell permeable small molecules, however, generally do not exploit these targets, owing to the difficulty in the design of high affinity, specific small molecules targeting RNA. As part of a general program to study RNA function using small molecules, we designed bioactive, modularly assembled small molecules that target the non-coding expanded RNA repeat that causes myotonic dystrophy type 1 (DM1), r(CUG) exp . Herein, we present a rigorous study to elucidate features in modularly assembled compounds that afford bioactivity. Different modular assembly scaffolds were investigated including polyamines, α-peptides, β-peptides, and peptide tertiary amides (PTAs). Based on activity as assessed by improvement of DM1-associated defects, stability against proteases, cellular permeability, and toxicity, we discovered that constrained backbones, namely PTAs, are optimal.

  转录组提供了大量潜在的RNA，可以成为治疗靶点或功能化学遗传探针的目标。然而，细胞可渗透的小分子通常不利用这些靶点，因为设计高亲和力、特异性小分子靶向RNA的困难。作为一个研究使用小分子研究RNA功能的普遍计划的一部分，我们设计了能够靶向导致肌萎缩性脊柱肌肉营养不良症类型1（DM1）的非编码扩展RNA重复物质r(CUG)exp的生物活性、模块化组装的小分子。在这里，我们提出了一项严谨的研究，以阐明模块化组装化合物中提供生物活性的特征。研究了不同的模块化组装支架，包括多胺、α-肽、β-肽和肽三级酰胺（PTAs）。根据通过改善DM1相关缺陷评估的活性、对蛋白酶的稳定性、细胞渗透性和毒性，我们发现受限制的骨架，即PTAs，是最佳的。
• [EN] MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] DÉRIVÉS D'INDOLE MACROCYCLIQUES UTILES COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：TIBOTEC PHARM LTD

  公开号：WO2010003658A1

  公开（公告）日：2010-01-14

  Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  HCV复制抑制剂的化学式（I），包括立体化学异构体形式，以及其盐、水合物、溶剂合物，其中R1、R2、R4、R5、R6和R7的含义如权利要求中所定义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HCV治疗中的应用。